0001209191-19-023170.txt : 20190403
0001209191-19-023170.hdr.sgml : 20190403
20190403163810
ACCESSION NUMBER: 0001209191-19-023170
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190401
FILED AS OF DATE: 20190403
DATE AS OF CHANGE: 20190403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stuart Iain
CENTRAL INDEX KEY: 0001727756
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36621
FILM NUMBER: 19729520
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd.
CENTRAL INDEX KEY: 0001606645
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
BUSINESS PHONE: 97289316233
MAIL ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
FORMER COMPANY:
FORMER CONFORMED NAME: Foamix Ltd.
DATE OF NAME CHANGE: 20140428
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-04-01
0
0001606645
Foamix Pharmaceuticals Ltd.
FOMX
0001727756
Stuart Iain
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLTZMAN STREET
REHOVOT
L3
7670402
ISRAEL
0
1
0
0
Chief Scientific Officer
Ordinary Shares
2019-04-01
4
S
0
1696
3.75
D
64475
D
For administrative reasons, the Reporting Person's then-existing long term incentives were amended in December 2018 to provide that, effective as of January 1, 2019, the vesting of any unvested restricted share units or options that were granted pursuant to such awards shall take place at the end of the calendar quarter in which the award was otherwise scheduled to vest.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
/s/ Mutya Harsch as attorney-in-fact for Iain Stuart
2019-04-03